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Basic science research into the mechanism of the development of endometriosis, its 20
persistence and resulting pain has begun to improve our understanding of how various 21
therapeutic options work.  While none of the available treatments resolves the underlying 22
disease process, there are a growing number of alternatives (1,2,3).  One of the more 23
recent classes of medical options includes the GnRH agonist and antagonists.  While at 24
present this class of medical options is the most expensive and involved in 25
implementation, they prove invaluable in terms of offering an aggressive, successful 26
alternative for many patients.  Furthermore, they may act directly on endometrial lesions in 27
a therapeutic manner.  This discussion will be oriented toward endometriosis pain 28
management, but many of the medical manipulations may be therapeutic for infertility 29
treatment as well if only by preventing the need for aggressive or emergency surgical 30
management of endometriosis, especially in young women.   31
32 
Pain symptomatology  and American Society of Reproductive Medicine (ASRM) staging 33
(4) or number of endometrial lesions have long been known to show no specific correlation 34
(5,6).  Yet, up to 60% of women with dysmenorrhea and 40-50% of women with 35
dyspareunia have endometriosis (7).  Thus, assessing improvement on an objective scale 36
by second look laparoscopy may not be as relevant as the clinical measure of pain relief, 37
though it has been utilized in double blind studies (8,9,10,11,12,13).  Hormonal 38
suppressive treatment, while effective for pain management, has no specific effectiveness 39
on endometriomas or pelvic adhesions. 40
41 
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Though the initiation of GnRH agonist therapy may dictate laparoscopic documentation of 42
endometriosis (14), second look laparoscopy is not a necessary part of clinical practice.  In 43
particular, because of the severity of side effects with  GnRH agonists, specific treatment 44
goals, as related to quality of life are important to maximize individual therapeutic success.  45
GnRH agonist or antagonist treatment is usually not considered a first line option for 46
treatment of endometriosis pain (14).  Cost as well as side effect profile dictate the use of 47
progestins, whether by oral, IM or IUD use, or oral contraceptives for ovarian suppression 48
as the first line therapy.  However, according to the ACOG Committee Opinion empiric 49
GnRH agonist treatment may be offered to patients older than 18 years.  If pain subsides, 50
then an empiric diagnosis of endometriosis can be made (14). 51
52 
GnRH agonists are potent down regulators of pituitary function, increasing initial release 53
then depletion of gonadotropin FSH and LH (15).  With regard to endometriosis, they are 54
believed to function by creating an estrogen deficient state by about 2 weeks after the 55
initiation of therapy (16).  There is growing scientific evidence that GnRH agonists may 56
have direct action on ovarian steroidogenesis independent of their action on the pituitary 57
and direct effects on endometrial implant growth.  Recent laboratory data utilizing biopsy 58
specimens of ectopic endometrium from 16 women with untreated endometriosis 59
confirmed direct action of GnRH agonists on ectopic endometrial  cells (17,18).  GnRH 60
agonist (leuprolide acetate) exposed cells showed increased apoptosis with decreasing 61
release of promitogenic cytokines such as Interleukin-1 Aeta (IL-1A) and Vascular 62
Endothelial Growth Factor (VEGF), both felt to be related to the growth of endometriosis.  63
These effects were reversed by the addition of antide, a  GnRH antagonist.  The vascular 64
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endothelial growth factor (VEGF) family of angiogenic molecules is involved in general 65
angiogenesis.   66
67 
Recent data suggests that VEGF may be involved in maintenance of endometriosis 68
(19,20).  Immunological factors working through Interleukin 1A [IL-1 A] may act as growth 69
factors as well as protecting cells from apoptotic demise.  Both have been measured as 70
elevated in the peritoneal fluid of women with endometriosis [21].  Furthermore, GnRH 71
receptors have been identified in ectopic endometrium (22) suggesting that GnRH may be 72
a direct regulator of endometriosis growth.  Iwabe et al demonstrated changes in 73
Interleukin-6 (IL-6) concentration in patients with ovarian endometriomas following 74
laparoscopic removal in 13 patients as well as with GnRH agonist (Buserelin) pre-surgical 75
treatment in 9  patients (23).  Matsuzaki et al found estrogen receptor alpha (ERa) mRNA 76
levels decreased in endometriomas after long term GnRH agonist treatment but not ER 77
beta (ER A) mRNA levels (24).  Others have demonstrated localized changes secondary 78
to GnRH agonist therapy whether in enzyme levels (25) or apoptosis (26).  These actions 79
of GnRH would explain in part the regression of endometrial lesions seen following GnRH 80
agonist therapy (17) as related to more than just the induced hypoestrogenic state.   81
82 
GnRH agonist therapy also influences eutopic endometrium function in patients with 83
endometriosis either as a consequence of the induced hypoestrogenic state (27) or by 84
direct action such as demonstrated by Wang et al (28).  The studies imply an autocrine – 85
paracrine action on local GnRH receptors within endometrium or ectopic endometrial 86
tissue.   87
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88 
The initial action of GnRH agonists is to cause a flare of pituitary FSH and LH which may 89
result in an exacerbation of endometriosis pain due to the ovarian stimulation.  Within two 90
weeks, the pituitary gonadotropins are exhausted and an estrogen deficient state is 91
obtained due to the lack of continued ovarian stimulation (29).  Concern regarding this 92
initial pain exacerbation dictates beginning treatment in the luteal phase of the cycle when 93
the ovary is less primed for stimulation.   94
95 
The importance of this initial flare effect of GnRH agonists has been evaluated.  Short term 96
endometriosis response to GnRH agonist treatment, in this case leuprolide 3.75mg, was 97
monitored.  Miller found an increase in endometriosis associated pain at 2 and 4 weeks 98
when the GnRH agonist was given in the early follicular phase (30).  Gelety et al confirmed 99
an exaggeration in the flare effect when the agonist was given in the early follicular phase 100 
as opposed to the late follicular phase (31).  Furthermore, Meldrum et al demonstrated that 101 
pituitary suppression was achieved more rapidly when GnRH agonist treatment was 102 
begun in the mid luteal phase (32).  Most studies document  no increase in pain after the 103 
first month of therapy (33,34). 104 
 105 
The rapid induction of an estrogen deficient state as profound as surgical menopause, 106 
accounts for most of the side effects related to GnRH agonist therapy (see table I).  Up to 107 
95% of patients experienced menopausal symptoms, the most common of which are hot 108 
flashes and insomnia (35,35a,35b,36,37).  Other symptoms less frequently noted  include 109 
vaginal dryness, mood changes, and headache.  Lipid changes include a decrease  in 110 
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HDL and increase in LDL.  These symptoms as well as the therapeutic effects occur for 111 
the most part regardless of the GnRH agonist utilized (Table II).   112 
 113 
Concern regarding bone loss has become the rate limiting change related to GnRH 114 
agonist therapy (14). Average bone loss of 4 to 6% detected after 6 months of GnRH 115 
agonist therapy (38,39,40) appears to be related to the hypoestrogenic state (41). While 116 
most people appear to regain bone density loss as estrogen levels return to normal with 117 
discontinuation of therapy, most authors have suggested a 6 month limit to GnRH agonist 118 
therapy (42,43,44).  Variability related to the reversibility of bone loss may be due to 119 
difference in the agonist utilized, the population studied (diet, lifestyle etc.), patient age (i.e. 120 
prior to attainment of peak BMD) or variability in bone mineral density as suggested by 121 
Pierce et al (45) and Matsuo (46).   122 
 123 
The concept of addback therapy with GnRH agonist treatment was initiated to help temper 124 
some of the hypoestrogenic side effects, in particular bone loss.  The “estrogen threshold 125 
hypothesis” of Barbieri (47) suggested that there was a specific estrogen threshold below 126 
which endometriosis was not stimulated, but hot flashes and bone loss were controlled.  127 
Titration of the specific hypoestrogenic level  while possible with nasal GnRH agonist 128 
(personal observation),  is not easily achieved with current intramuscular  GnRH agonists 129 
on the market. 130 
 131 
The concept of adding back small quantities of estrogen to ease symptoms, but not 132 
compromise treatment efficacy, assumes that an estrogen threshold is constant for most 133 
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women. Multiple regimens have been described including estrogen in the form of Premarin 134 
0.625mg or estradiol 1mg to progestins, norethindrone acetate in doses from 2.5mg to 135 
10mg daily and other progestins (48,49,50).  Biphosphonates have been added  as well 136 
(51,52)(Table III).  All have shown adequate safety profiles with regard to bone 137 
maintenance for up to one year of GnRH agonist use.  Equivalent clinical efficacy has 138 
been shown with 6 months treatment of GnRH agonist with or without the use of addback 139 
therapy without compromising pain relief (40,44,49,53).   140 
 141 
However, while not all patients experience vasomotor symptom relief with addback 142 
therapy, many find significant changes that make the treatment tolerable (54).  Adverse 143 
effects of the addback treatment are more prevalent with higher doses. Premarin in a dose 144 
of 1.25mg caused women to discontinue treatment to due to pain recurrence (49). 145 
Androgenic side effects were induced with norethindrone acetate in a dose of 10mg per 146 
day (51).  Calcium supplementation is essential as part of a bone maintenance program. 147 
Bone density measurement is suggested as part of appropriate follow-up to long term 148 
GnRH agonist and addback therapy (greater than one year).   149 
 150 
Studies have been done with all of the different GnRH agonists available on the market.  151 
Although the various formulations are delivered by different routes of administration and 152 
different dosages, ovarian suppression is produced by all with little difference in side 153 
effects or efficacy (1,3,55,56).   154 
 155 
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Pain relief efficacy studies comparing GnRH agonists with danazol, the previous gold 156 
standard, or placebo, have been significant. When compared to placebo, leuprolide 157 
acetate was highly effective in a 6 month trial (35).  Studies comparing various GnRH 158 
agonists with danazol, all have shown equivalent pain relief (8,10,11,12,55,56,57,58,59). 159 
 160 
GnRH Antagonists 161 
 162 
GnRH antagonists are now utilized routinely as part of controlled ovarian hyperstimulation 163 
protocols for assisted reproduction and  fertility treatments. GnRH antagonists work by 164 
competitive blocking of pituitary GnRH receptors (3,60). Their action onset is immediate, 165 
time related and reversible. There is no initial flare of gonadotropins either before or after 166 
the onset of action.  But unlike GnRH agonists, gonadotropins are not depleted though the 167 
similar end effect of a hypoestrogen state is achieved (61). 168 
 169 
Recent laboratory studies comparing the effects of GnRH agonists with GnRH antagonists 170 
on eutopic endometrial cells in women with and without endometriosis showed no direct 171 
effects from the antagonists as opposed to the agonists which demonstrated increased 172 
apoptosis and decreased cytokines (17).  Interestingly, the addition of a GnRH antagonist 173 
blocked the down regulation effects of the GnRH agonist on the eutopic endometrial tissue 174 
from both endometriosis patients and controls supporting the thesis that direct effects of 175 
GnRH agonists in vitro are probably mediated by local GnRH receptor interaction. 176 
 177 
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Most available clinical forms of GnRH antagonists offer short term (daily or three day) 178 
dosing as part of infertility treatment.  While theoretically GnRH antagonists should be 179 
applicable to endometriosis treatment, as yet few studies have been published.  Recent 180 
work by Kupker et al (62) utilized subcutaneous injections of a GnRH antagonist 181 
(cetrorelix) in 15 patients with pain related to endometriosis.  A 3mg once weekly dose 182 
over 8 weeks was utilized.  Serum estradiol levels ranged around 50 pg/mL during 183 
therapy. All patients were symptom free during the treatment period.  Subsequent 184 
laparoscopy confirmed regression in 60% of cases (9/15) with a significant decline in stage 185 
of endometriosis from stage III to stage II.   186 
 187 
Based on this, Donnez et al (63) ( reported on a dose finding study for a GnRH antagonist, 188 
cetrorelix, given over a period of 8 weeks in the treatment of endometriosis.  Sixty women 189 
with laparoscopy proven endometriosis and moderate to severe symptoms were included 190 
in the 8 week trial.  Weekly or bi-weekly doses of cetrorelix, 5 mg or 10 mg, were utilized.  191 
All resulted in a rapid decrease in endometriosis symptoms by 4 weeks of treatment and 192 
the effect continued until 16 weeks based on pain and dysmenorrhea scores.  Treatment 193 
was well tolerated except for one local injection site irritation.  As the authors note, the 194 
absence of a flare effect with treatment initiation allows for dose free intervals to be 195 
interspersed without risk of exacerbation if retreatment is postponed until symptoms recur.  196 
This may allow for an interesting approach to treatment. Development of GnRH antagonist 197 
with long term action may be of use for such treatments and is supposedly in progress.   198 
 199 
Batzer FR   
GnRH Agonist and Antagonist:  Options for Endometriosis Pain and Treatment 5.24.2007 
10
There is recent research regarding a second type of GnRH, GnRH II which occurs 200 
throughout peripheral tissues in the female reproductive tract including the placenta, 201 
endometrium and granulosa cells of the ovary as well as central nervous system.  202 
According to studies by Morimoto et al (64) levels of GnRH II mRNA were lower in 203 
endometrial and endometriotic tissue of women with endometriosis than in those without 204 
endometriosis.  Since the effect of GnRH II is anti-proliferative and anti-inflammatory, its 205 
decreased presence in patients with endometriosis suggests another deficient protective 206 
mechanism leading to disease development.  The addition of GnRH antagonists (antide) 207 
blocked GnRH I and GnRH II action in this study, suggesting a specific local effect of 208 




Treatment with a GnRH agonist does provide proven pain relief in 80-90% of women with 213 
documented endometriosis, but medical treatment is suppressive therapy, not extirpative 214 
therapy (65) and pain does recur. Though recent evidence suggests a direct effect of 215 
GnRH agonist on endometriosis lesions, the addition of medical treatment to conservative 216 
surgery pain management has shown extended relief when employed for 6 months or 217 
more (65,66).   218 
 219 
GnRH agonist therapy has proven efficacious in the treatment of pain related to 220 
endometriosis. The addition of immediate addback therapy as well as preventing  bone 221 
loss, appears to improve compliance and tolerability without sacrificing the therapeutic aim 222 
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of pain relief.  In this combination, GnRH agonist therapy deserves consideration as first 223 
line therapy for proven endometriosis pain relief.  Further development of long acting 224 
GnRH antagonists for endometriosis treatment deserves attention due to the immediacy of 225 
onset, ease of reversibility and lack of pain increase (flare) with utilization. 226 
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Table I.  Side Effects of GnRH Agonists403 
• Hot flashes (80%-90%) 404 
• Sleep disturbances (60%-90%) 405 
• (30%) Vaginal dryness 406 
• Joint pain (30%) 407 
• Breakthrough bleeding (20%-30%) 408 
• Headaches (20%-30%) 409 
• Mood change (10%) 410 
• Bone loss (T bone density 5%-6%) 411 
• Adverse lipid changes (U LDL, T HDL) 412 
Estimates of prevalence are a composite from published clinical trials (34,35,38)   413 
 414 
Modified from Mahutte NG and Arici A. Obstet Gynecol Clin N Am 2003;30:133-150 (3) 415 
